
Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction
Eli Lilly and Company (NYSE: LLY) has announced positive results from two phase 3 clinical trials, QWINT-1 and QWINT-3, evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes. The trials assessed efsitora’s efficacy in individuals starting insulin…













